Biogen investigated by Italian regulator over multiple sclerosis ‘market abuse’ claims

Italy’s antitrust agency, the Italian Competition Authority (AGCM), is investigating Biogen and its Italian subsidiary over claims it is abusing its market position regarding a test for its multiple sclerosis drug Tysabri (natalizumab).